Beth L. Abramson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Beth L. Abramson has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Chi-Ming Chow
2 shared publicationsAiala Barr
Division of General Internal Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario
1 shared publicationAlexander G Turpie
1 shared publicationAndre Roussin
1 shared publicationAnil Gupta
1 shared publicationAsad Junaid
1 shared publication
Latest Publications
- 1 September 2017
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 11 (5) , 1201-1211
Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial
- 1 September 2017
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 11 (5) , 1201-1211
Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial
- 1 December 2009
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 25 (12) , e428
Mitral and tricuspid valve papillary fibroelastomas: A rare cause of multiple intracardiac masses
- 1 December 2009
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 25 (12) , e428
Mitral and tricuspid valve papillary fibroelastomas: A rare cause of multiple intracardiac masses
- 1 September 2008
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 24 (9) , 677-682
Cardiovascular risk factor awareness in a disadvantaged inner-city population – implications for preventive strategies
- 1 September 2008
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 24 (9) , 677-682
Cardiovascular risk factor awareness in a disadvantaged inner-city population – implications for preventive strategies
- 1 October 2005
- Vol. 21 (12) , 997-1006
Canadian Cardiovascular Society Consensus Conference: peripheral arterial disease - executive summary.
This Consensus Conference has been supported by the Canadian Cardiovascular Society. The process is dynamic, with intentional structure that requires peer review and feedback from cardiovascular specialists across Canada. The writing and review panel encompassed a broad range of specialists caring for the patient with peripheral arterial disease (PAD). PAD is an often asymptomatic, underdiagnosed, under-recognized and undertreated condition. It is associated with significant morbidity and cardiac mortality. Until recently, little attention has focused on the evaluation and treatment of the disease process itself. The goal of the present paper is to ensure better treatment, to reduce both morbidity and mortality in the patient with vascular disease and, importantly, to serve as a guide to the busy clinician. Although the focus is PAD, there are chapters on thoracic and abdominal aortic disease, renal arterial disease and the evidence supporting management. Screening and diagnostic techniques including history and physical examination as well as noninvasive imaging techniques are reviewed. Medical management for patients with vascular disease including prevention and risk reduction is graded based on evidence, including both pharmacological and nonpharmacological management strategies, followed by an introduction to newer percutaneous techniques. Finally, surgical treatment for claudication including new concepts on the perioperative risk assessment for patients undergoing major vascular surgery is discussed.
- 1 October 2005
- Vol. 21 (12) , 997-1006
Canadian Cardiovascular Society Consensus Conference: peripheral arterial disease - executive summary.
This Consensus Conference has been supported by the Canadian Cardiovascular Society. The process is dynamic, with intentional structure that requires peer review and feedback from cardiovascular specialists across Canada. The writing and review panel encompassed a broad range of specialists caring for the patient with peripheral arterial disease (PAD). PAD is an often asymptomatic, underdiagnosed, under-recognized and undertreated condition. It is associated with significant morbidity and cardiac mortality. Until recently, little attention has focused on the evaluation and treatment of the disease process itself. The goal of the present paper is to ensure better treatment, to reduce both morbidity and mortality in the patient with vascular disease and, importantly, to serve as a guide to the busy clinician. Although the focus is PAD, there are chapters on thoracic and abdominal aortic disease, renal arterial disease and the evidence supporting management. Screening and diagnostic techniques including history and physical examination as well as noninvasive imaging techniques are reviewed. Medical management for patients with vascular disease including prevention and risk reduction is graded based on evidence, including both pharmacological and nonpharmacological management strategies, followed by an introduction to newer percutaneous techniques. Finally, surgical treatment for claudication including new concepts on the perioperative risk assessment for patients undergoing major vascular surgery is discussed.
- Open Access
- 5 February 2003
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 3 (1) , 1
Management of congestive heart failure: a gender gap may still exist. Observations from a contemporary cohort
Unlike other cardiovascular diseases the incidence and prevalence of congestive heart failure (CHF) continues to increase. While gender differences in coronary artery disease have been well described, to date, there has been a relative paucity of similar data in patients with CHF. We conducted a pilot study to evaluate the profile and management of patients with CHF at a tertiary care centre to determine if a gender difference exists. A chart review was performed at a tertiary care centre on consecutive patients admitted with a primary diagnosis of CHF between June 1997 and 1998. Co-morbidity, diagnostic investigations, and management of CHF were recorded. Comparisons between male and female patients were conducted. One hundred and forty five patients were reviewed. There were 80 male (M) and 65 female (F) patients of similar age [71.6 vs. 71.3 (M vs. F), p = NS]. Male patients were more likely to have had a previous myocardial infarction (66% vs. 35%, p < 0.01) and revascularization (41% vs. 20%, p < 0.05), and had worse left ventricular ejection fraction (LVEF) than women, [median LVEF 3 vs. 2 (M vs. F), p < 0.01]. Male patients were more likely to have a non-invasive assessment of left ventricular (LV) function [85% vs. 69%, (M vs. F), p < 0.05]. A logistic regression analysis suggests that amongst those without coronary disease, males were more likely to receive non-invasive testing. There were no differences in the use of prescribed medications, in this cohort. This pilot study demonstrated that there seem to be important gender differences in the profile and management of patients with CHF. Importantly women were less likely to have an evaluation of LV function. As assessment of LV function has significant implications on patient management, this data justifies the need for larger studies to assess gender differences in CHF profile and treatment.
- 5 February 2003
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 3 (1) , 1
Open AccessManagement of congestive heart failure: a gender gap may still exist. Observations from a contemporary cohort
Unlike other cardiovascular diseases the incidence and prevalence of congestive heart failure (CHF) continues to increase. While gender differences in coronary artery disease have been well described, to date, there has been a relative paucity of similar data in patients with CHF. We conducted a pilot study to evaluate the profile and management of patients with CHF at a tertiary care centre to determine if a gender difference exists. A chart review was performed at a tertiary care centre on consecutive patients admitted with a primary diagnosis of CHF between June 1997 and 1998. Co-morbidity, diagnostic investigations, and management of CHF were recorded. Comparisons between male and female patients were conducted. One hundred and forty five patients were reviewed. There were 80 male (M) and 65 female (F) patients of similar age [71.6 vs. 71.3 (M vs. F), p = NS]. Male patients were more likely to have had a previous myocardial infarction (66% vs. 35%, p < 0.01) and revascularization (41% vs. 20%, p < 0.05), and had worse left ventricular ejection fraction (LVEF) than women, [median LVEF 3 vs. 2 (M vs. F), p < 0.01]. Male patients were more likely to have a non-invasive assessment of left ventricular (LV) function [85% vs. 69%, (M vs. F), p < 0.05]. A logistic regression analysis suggests that amongst those without coronary disease, males were more likely to receive non-invasive testing. There were no differences in the use of prescribed medications, in this cohort. This pilot study demonstrated that there seem to be important gender differences in the profile and management of patients with CHF. Importantly women were less likely to have an evaluation of LV function. As assessment of LV function has significant implications on patient management, this data justifies the need for larger studies to assess gender differences in CHF profile and treatment.
- 1 December 2002
- Published by Rockefeller University Press
- Vol. 9 (6) , 309-14
Postmenopausal hormone replacement therapy and the prevention of cardiovascular disease: a review.
The role of hormone replacement therapy (HRT) for the prevention of cardiac disease is contentious. In this review the epidemiological evidence for the role of HRT in primary and secondary prevention of cardiac disease is assessed. Although current studies suggest very little role for HRT in women with established cardiac disease, its use in the 'healthy woman' without vascular disease until recently was not clear. HRT for the sole purpose of prevention of cardiac disease is now not indicated.
- 1 December 2002
- Published by Rockefeller University Press
- Vol. 9 (6) , 309-14
Postmenopausal hormone replacement therapy and the prevention of cardiovascular disease: a review.
The role of hormone replacement therapy (HRT) for the prevention of cardiac disease is contentious. In this review the epidemiological evidence for the role of HRT in primary and secondary prevention of cardiac disease is assessed. Although current studies suggest very little role for HRT in women with established cardiac disease, its use in the 'healthy woman' without vascular disease until recently was not clear. HRT for the sole purpose of prevention of cardiac disease is now not indicated.
- 1 December 2002
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 9 (6) , 309-314
Postmenopausal Hormone Replacement Therapy and the Prevention of Cardiovascular Disease: A Review
The role of hormone replacement therapy (HRT) for the prevention of cardiac disease is contentious. In this review the epidemiological evidence for the role of HRT in primary and secondary prevention of cardiac disease is assessed. Although current studies suggest very little role for HRT in women with established cardiac disease, its use in the ‘healthy woman’ without vascular disease until recently was not clear. HRT for the sole purpose of prevention of cardiac disease is now not indicated.
- 1 December 2002
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 9 (6) , 309-314
Postmenopausal Hormone Replacement Therapy and the Prevention of Cardiovascular Disease: A Review
The role of hormone replacement therapy (HRT) for the prevention of cardiac disease is contentious. In this review the epidemiological evidence for the role of HRT in primary and secondary prevention of cardiac disease is assessed. Although current studies suggest very little role for HRT in women with established cardiac disease, its use in the ‘healthy woman’ without vascular disease until recently was not clear. HRT for the sole purpose of prevention of cardiac disease is now not indicated.
- 1 May 2000
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 7 (3) , 205-212
Stress perfusion/metabolism imaging: A pilot study for a potential new approach to the diagnosis of coronary disease in women
- 1 May 2000
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 7 (3) , 205-212
Stress perfusion/metabolism imaging: A pilot study for a potential new approach to the diagnosis of coronary disease in women